Procedures
Cancer, tumor, mg/mTumor
DISEASE PROGRESSION, TUMOR, ADVERSE EVENT, ADVERSE EVENTS, BLOOD, CANCER
At the screening stage, all patients underwent enhanced computed tomography (CT) of the chest, abdomen, and pelvis; enhanced magnetic resonance imaging (MRI) of the head and neck; bone scan; or Apatinib was orally administered at 500 mg once per day continuously, and capecitabine was orally administered at 1000 mg/mTumor response was assessed by imaging tests, including enhanced CT or MRI, every two treatment cycles until disease progression or withdrawal for any reason. The response was confirmed by at least one sequential tumor assessment using RECIST v1.1. Blood, urine, and biochemical tests were required at the end of each cycle. All adverse events (AEs) were monitored throughout the treatment and 30 days thereafter and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0.